Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD
Status:
Recruiting
Trial end date:
2024-06-27
Target enrollment:
Participant gender:
Summary
This is a pivotal phase 3 study designed to support an indication for the reduction of
cardiovascular risk in patients with established CVD and elevated Lp(a)